| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 5 securities · may seek to influence control | ||||||
|
enVVeno Medical Corp
13D/A
NVNO · 29415J205
|
0% |
9/15/2026
Event 9/11/2026
|
||||
| Braeden Lichti | 0% | |||||
| Northstrive Fund II LP | 0% | |||||
|
PMGC Holdings Inc.
13D/A
ELAB · 73017P508
|
7.4% |
6/3/2026
Event 6/1/2026
|
||||
| Braeden Lichti | 7.4% | |||||
| Northstrive Companies Inc. | 7.4% | |||||
|
Bluejay Diagnostics, Inc.
13D/A
BJDX · 095633608
|
0% |
6/2/2026
Event 6/2/2026
|
||||
| Braeden Lichti | 0% | |||||
| Northstrive Fund II LP | 0% | |||||
|
PMGC Holdings Inc.
13D
28622K302
|
52.4% |
3/28/2025
Event 3/26/2025
|
||||
|
PMGC Holdings Inc.
13D/A
ELAB · 73017P201
|
0.2% |
3/28/2025
Event 9/24/2024
|
||||
| Schedule 13G · 1 security · passive | ||||||
|
Enveric Biosciences, Inc.
13G/A
ENVB · 29405E505
|
0% |
12/10/2025
Event 12/9/2025
|
||||
| Braeden Lichti | 0% | |||||
| Northstrive Fund II LP | 0% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.